Interestingly, a recent study conducted by Izadi et al (2021)32 on 6077 patients from 74 countries showed that, when compared to other frequently prescribed immunomodulatory management regimens, TNF inhibitor monotherapy was linked with a reduced risk of unfavorable COVID‐19 outcomes in individuals with immune‐mediated inflammatory diseases. This evidence concerns the gene TNF and COVID-19.